Interim report January-September 2007

Interim report January-September 2007

• Net sales increased by 9 percent to SEK 141.4 (129.5) million. Adjusted for
exchange rate effects, the increase was 12 percent. During the third quarter
sales amounted to SEK 44.6 (41.0) million, corresponding to an increase of 9
percent. Adjusted for negative exchange rate effects, the increase was 12
percent.

• Gross income increased by 11 percent to SEK 97.5 (87.6) million, and the gross
margin improved to 69 percent (68). Gross income for the third quarter increased
by 7 percent to SEK 30.5 (28.4) million and the gross margin was 68 (69)
percent, despite extra costs in connection with the launch of a completely new
product series.

• Operating income increased by 11 percent and amounted to SEK 17.9 (16.1)
million, which gives an operating margin of 13 percent (12). For the third
quarter operating income amounted to SEK 4.1 (6.5) million.

• Operating income before research and development costs increased by 10 percent
to SEK 37.5 (34.2) million. This corresponds to a margin of 27 percent (26). For
the third quarter operating income before research and development costs
amounted to SEK 10.5 (12.6) million, a margin of 24 percent (31).

• Continued strong focus on research and development activities, 13.9 percent
(14.0) of sales, 14.4 percent (14.9) for the third quarter.

• Consolidated net income increased to SEK 28.2 (13.1) million, of which SEK 7.7
(6.0) million was for the third quarter. Capitalization of the deferred tax
asset in loss carry-forward for tax purposes has been carried out to the tune of
SEK 12.3 (-) million, of which SEK 4.1 (-) million was for the third quarter.

• The cash flow from operating activities amounted to SEK 18.0 (18.4) million,
of which SEK 5.6 (9.9) was for the third quarter.

• Earnings per share increased to SEK 1.42 (0.66) of which SEK 0.39 (0.30) was
for the third quarter.

• The equity/assets ratio amounted to 83 percent (79).

• Launch of a new product series within Fertility, the G5 Series™.



October 25, 2007
Kungsbacka, Sweden 

Magnus Nilsson
CEO


Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.